| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The molecular targets of BCN-endo-PEG4-NHS are chemical functional groups, not biological targets. The NHS ester is reactive towards primary amine groups (-NH2) found on the N-terminus of proteins and on lysine side chains, allowing covalent attachment to antibodies or other proteins. The BCN group is reactive towards azide groups (-N3) via copper-free click chemistry (SPAAC), enabling conjugation to azide-functionalized payloads. The PEG4 spacer is non-immunogenic, increases hydrophilicity, and reduces steric hindrance. Thus, this compound is a linker for constructing ADCs and other bioconjugates. It has no intrinsic biological activity.
|
|---|---|
| ln Vitro |
BCN-endo-PEG4-NHS itself is not a biologically active compound. Its "in vitro activity" refers to conjugation efficiency. The conjugation efficiency to an antibody is measured by drug-to-antibody ratio (DAR) using hydrophobic interaction chromatography (HIC) or LC-MS. Typical reaction: antibody (5 mg/mL) in PBS pH 7.2-7.4, BCN-endo-PEG4-NHS dissolved in DMSO (10-50 mM) added at 5-15:1 molar excess, incubated at 4degC or room temperature for 2-4 h, quenched with Tris buffer. BCN-labeled antibody is purified by size-exclusion chromatography. Conjugation efficiency typically >80-90%. Then BCN-labeled antibody is conjugated to azide-functionalized payload via copper-free click chemistry (37degC, 2-24 h). Final ADC is analyzed by HIC or LC-MS for DAR. The ADC's activity is tested in cell viability assays.
|
| Enzyme Assay |
A typical non-cellular assay is a click chemistry efficiency test using a model azide compound, such as azide-functionalized fluorescent dye (e.g., TAMRA-azide). BCN-endo-PEG4-NHS (or BCN-labeled protein) is mixed with TAMRA-azide in 1:1 to 1:5 molar ratio in PBS at 37degC for 2 h. The reaction mixture is analyzed by SDS-PAGE (for BCN-labeled protein) and fluorescence scanning to detect TAMRA signal, indicating successful conjugation. For small molecules, reaction can be monitored by HPLC or LC-MS. Reaction efficiency is calculated by comparing product peak area to starting material. Copper-free click chemistry between BCN and azide is efficient and rapid (1-2 h at 37degC).
|
| Cell Assay |
In vitro cell-based assays for BCN-endo-PEG4-NHS are not performed on the linker itself. For an ADC constructed using this linker, standard cytotoxicity assays are performed on target cell lines. For example, if an anti-HER2 antibody is used, the ADC is tested on HER2-positive SK-BR-3 cells. Cells are seeded in 96-well plates and treated with serial dilutions of the ADC (0.001-100 nM). After 96 h, cell viability is measured using CellTiter-Glo. IC₅0 is calculated. The ADC's efficacy should be blocked by competition with excess unconjugated antibody, confirming target-specific killing.
|
| Animal Protocol |
An in vivo animal study for an ADC constructed using this linker follows standard ADC efficacy protocols. For a HER2-targeting ADC, female BALB/c nude mice bearing BT-474 or SK-BR-3 xenografts are used. When tumors reach ~150 mm3, mice are randomized (n=8-10). The ADC is formulated in 10 mM histidine buffer (pH 5.5) with 5% trehalose and 0.01% Tween-80, and administered intravenously at 1, 3, 10, 30 mg/kg once weekly for 3 weeks. Tumor volume is measured twice weekly. Body weight is monitored. Tumor growth inhibition (TGI) is calculated. At study end, tumors are excised for Ki-67 and TUNEL staining. All procedures require IACUC approval.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of BCN-endo-PEG4-NHS itself are not relevant, as it is a linker that is consumed during conjugation and not administered to animals or humans. The PK of an ADC made with this linker is similar to other ADCs: long half-life (days), low clearance, low volume of distribution. The linker is stable in circulation, with minimal payload release in bloodstream. It is designed to be non-immunogenic and biodegradable.
|
| Toxicity/Toxicokinetics |
No toxicity data is available for BCN-endo-PEG4-NHS itself, as it is a chemical linker. The NHS ester is reactive and can be an irritant and sensitizer. Standard safety precautions (gloves, lab coat, eye protection) should be used. It is for research use only.
|
| Additional Infomation |
BCN-endo-PEG4-NHS is not an approved drug. It is a research-grade chemical linker used for the synthesis of ADCs and other bioconjugates. Its mechanism is based on orthogonal conjugation chemistry: NHS ester for conjugation to amines on proteins, and BCN group for copper-free click chemistry with azides. The PEG4 spacer provides water solubility and flexibility. This linker is a valuable tool for chemical biology, targeted drug delivery, and ADC development. No clinical trials have been registered for this linker. For research use only; not for human therapeutic use.
|
| Molecular Formula |
C26H38N2O10
|
|---|---|
| Molecular Weight |
538.59
|
| Exact Mass |
538.252
|
| CAS # |
1702356-19-1
|
| PubChem CID |
121242067
|
| Appearance |
Colorless to light yellow viscous liquid
|
| Density |
1.28±0.1 g/cm3(Predicted)
|
| LogP |
0.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
38
|
| Complexity |
833
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O(C(NCCOCCOCCOCCOCCC(=O)ON1C(CCC1=O)=O)=O)CC1[C@H]2CCC#CCC[C@H]21
|
| InChi Key |
MFQCOKMBYCIQEJ-CBQGHPETSA-N
|
| InChi Code |
InChI=1S/C26H38N2O10/c29-23-7-8-24(30)28(23)38-25(31)9-11-33-13-15-35-17-18-36-16-14-34-12-10-27-26(32)37-19-22-20-5-3-1-2-4-6-21(20)22/h20-22H,3-19H2,(H,27,32)/t20-,21+,22?
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[[(1S,8R)-9-bicyclo[6.1.0]non-4-ynyl]methoxycarbonylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8567 mL | 9.2835 mL | 18.5670 mL | |
| 5 mM | 0.3713 mL | 1.8567 mL | 3.7134 mL | |
| 10 mM | 0.1857 mL | 0.9284 mL | 1.8567 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
